HSF1 and anemia (phenotype): This was clinically highlighted by lymphocytosis and anemia, so that this patient has been initiated to a salvage treatment based on venetoclax, as reported in Figure 4C. Another evidence supporting the hypothesis that HSP70 and HSF1 may be markers of disease progression is reported in Figure 4D; here, HSP70 and HSF1 overexpression is associated with a major resistance to ibrutinib, as assessed by IC50 calculation in CLL B cells from therapy free patients.